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ABSTRACT
BACKGROUND: Amoxicillin, a semisynthetic penicillin antibiotic, is widely
prescribed in Bangladesh due to its extended spectrum and its rapid and extensive oral
absorption with good tolerability. Although a number of generic oral formulations of
amoxicillin are available in Bangladesh, a study of the bioequivalence and pharrnaco-
kinetic properties of these formulations has not yet been conducted in a Bangladeshi
population.
OBJECTIVE: The aim of this study was to assess the pharmacokinetic properties
and bioequivalence of 2 formulations of amoxicillin 500-mg capsules (test, SK-mox®;
reference, Amoxil-Bencard'") using serum data.
METHODS: This single-dose, randomized, open-label, 2-period crossover study
was conducted in healthy male subjects in compliance with the Declaration of
Helsinki and International Conference on Harmonisation guidelines. Subjects were
assigned to receive the test or the reference drug as a single-dose, 500-mg capsule
under fasting conditions after a l-week washout period. After oral administration,
blood samples were collected and analyzed for amoxicillin concentration using a vali-
dated high-performance liquid chromatography method. The pharmacokinetic parame-
ters were determined using a noncompartmental method. The formulations were
considered bioequivalent if the natural log-transformed ratios of pharmacokinetic pa-
rameters were within the predetermined equivalence range of 80% to 125%, according
to the US Food and Drug Administration (FDA) requirement.
RESULTS: Twenty-four healthy adult male Bangladeshi volunteers (mean [SD}
age, 26.92 [3.37} years; age range, 23-34 years; mean [SD} body mass index,
23.09 [1.58} kg/rn') participated in the study. Using serum data, the values obtained
for the test and reference formulations, respectively, were as follows: C
max
' 9.85 (2.73)
and 10.63 (2.12) pg/mL; Tmax, 1.29 (0.58) and 1.33 (0.49) hours; and AUCO_ 12'
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27.09 (7.62) and 28.56 (6.30) JIg/mL . h". No period, sequence, or formulation
effects were observed; however, significant variation was found among subjects with
regard to AUCO_ 12 (P < 0.001), AUCo-oo (P = 0.002), area under the moment curve
(AUMC) from 0 to 12 hours (P < 0.001), and AUMCo-oo (P = 0.017). All CIs for the
parameters measured were within the FDA-accepted limits of 80% to 125%.
CONCLUSION: The present study suggests that the test 500-mg amoxicillin
capsule was bioequivalent to the reference 500-mg capsule according to the FDA
regulatory definition, in this population of healthy adult male Bangladeshi volun-
teers. (Curr Ther Res Clin Exp. 2008;69:504-513) © 2008 Excerpta Medica Inc.
KEY WORDS: amoxicillin, pharmacokinetic, bioequivalence, analysis of variance,
confidence interval, Bangladeshi population.
INTRODUCTION
The use of generic drugs is of increasing importance, in terms of efficacy, in the
selection of therapeutic alternatives. However, their use in clinical practice de-
pends not only on their similarity (in terms of formulation, composition, and
bioequivalence, as considered by regulatory agencies), but also their interchange-
ability with their reference drugs. Amoxicillin is a widely prescribed antimicrobial
agent because of its extended spectrum, rapid and extensive oral absorption, and
good tolerability. 1 Several in vitro studies have reported that the bactericidal activi-
ty of amoxicillin is significantly better than that of other 13-lactam antibiotics
(eg, penicillin G, cefpodoxime, cefprozil, cefac1or) against penicillin-susceptible
and -resistant pneumococci.e-' Oral absorption of amoxicillin is -90%, and a peak
serum concentration of 10 mg/L is attained within 1 to 2 hours with a 500-mg
oral dose. 4 The t 1l2 of amoxicillin in healthy volunteers has been reported to be
-60 minutes.P Approximately 10% to 20% of the absorbed dose is hydrolyzed to
the corresponding penicilloic acid, and 75% of the unchanged drug is excreted
through urine.f
The pharmacokinetics of amoxicillin have been reported in various populations
including Germans." Americans,8-10 Brazilians,l1,12 and Belgians.l ' but not in the
Bangladeshi population. The aim of the study was to compare the oral absorption
and disposition kinetics of a rest" and reference! formulation of amoxicillin 500-mg
capsules in healthy Bangladeshi volunteers using serum data.
SUBJECTS AND METHODS
MATERIALS
Amoxicillin and cefaclor (internal standard) provided by Eskayef Bangladesh Ltd.,
(Dhaka, Bangladesh) were used for the study. High-performance liquid chroma-
tography (HPLC)-grade acetonitrile and methanol were purchased from Fisher Scien-
tific (Loughborough, United Kingdom). Deionized water was prepared using a water
*Trademark: SK-mox® (Eskayef Bangladesh Lcd., Dhaka, Bangladesh; Batch #7003).
"Trademark: Arnoxil-Bencard'" (SmithKline Beecham pic, Middlesex, United Kingdom; Batch #B.526003).
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purification system (Arium'" 611, Sartorius AG, Goettingen, Germany). All other
chemicals were of analytical grade and were used without further purification.
SUBJECTS
Nonsmoking healthy adult male Bangladeshi volunteers were enrolled in the study.
Subjects were eligible for the study if they had an unremarkable prestudy medical
history, physical examination (height, weight, and temperature), and normal cardiac
(heart rate, blood pressure, echocardiogram [ECG]), hepatic (enzyme function stud-
ies), renal (creatinine clearance), pulmonary (respiratory rate), neurologic, gastrointes-
tinal, and hematologic profiles. All subjects had to report abstinence from other medi-
cations, alcohol, tobacco, and caffeinated products throughout the study. Exclusion
criteria were a previous history of hypersensitivity to any of the penicillins, having
donated blood within 30 days prior to dosing, and vomiting or any other adverse
events (AEs) during the 12-hour study period.
STUDY DESIGN AND CLINICAL CONDUCT
The study was conducted in the Department of Clinical Pharmacy and Pharmacolo-
gy, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh, in accordance
with the International Conference on Harmonisation Guideline for Good Clinical
Practice l 4 and in compliance with the Declaration of Helsinki and its amendments. IS
The Bangladesh Medical Research Council (Dhaka, Bangladesh) provided ethical per-
mission for approval of the protocol and consent form for the clinical investigation.
Each volunteer signed an informed consent document before entering the study and
was free to withdraw from the study at any time without any obligation.
The study was a single-dose, randomized, open-label, 2-period crossover design
with a I-week washout period. A single 500-mg capsule of either formulation
(SK-mox or Amoxil-Bencard) was administered with 250 mL of water after an overnight
fast. A standardized breakfast and lunch were given at 4 and 8 hours after administra-
tion, respectively. Patients were followed up for 12 hours after study drug administra-
tion. None of the volunteers vomited and no AEs were identified or reported.
Venous blood samples were obtained prior to dosing (hour 0) and 0.5, 1, 1.5,2,3,
4, 5, 6, 8, 10, and 12 hours after dosing in both periods. Serum was separated by
centrifugation and stored at -4O°C until analysis.
BIOANALYSIS
Amoxicillin and cefaclor (internal standard) were extracted from human plasma
samples by protein precipitation with slight modification of the method described by
Pires de Abreu et al. l 2 A 200-pL aliquot of each plasma sample was transferred to a
polypropylene tube (Eppendorf, Hamburg, Germany), and 60 ul, of cefaclor solution
(100 pg/mL) and 340 pi of methanol were added. After brief vortex mixing, the tubes
were centrifuged at 10,000 rpm for 5 minutes. Then the supernatants were collected
and 20 pL was injected into the chromatographic system.
An HPLC system consisting of an SCL-lOAvp system controller and 2 LC-8A
pumps (Shimadzu Corp., Columbia, Maryland) was used to quantify amoxicillin in
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serum samples. The drug analysis data were acquired and processed using LC
Solution version 1.03 SP3 software (Shimadzu Corp.). Ultraviolet (UV) detection
was achieved using an SPD-10Avp UV-Visible detector (Shimadzu Corp.). The
mobile phase involved a mixture of monobasic potassium phosphate buffer (pH 5.0)
and acetonitrile (95:5) pumped at a flow rate of 1.5 mLimin through the column
(Nuc1eosil C 18 , 5 p , 4.6 x 250 mm, Varian Inc., Palo Alto, California) at room
temperature. Peaks were monitored using UV absorbance at 230 nm at a sensi-
tivity of 0.0005 absorbance units full scale. Quantification of amoxicillin in
serum samples was obtained by plotting the amoxicillin to internal standard peak
area ratio as a function of amoxicillin concentration. The analytical method was
validated in terms of specificity, linearity, precision, accuracy, extraction effi-
ciency, and stability.
TOLERABILITY
Tolerability was determined by clinical assessment and monitoring vital signs
(blood pressure, heart rate, body temperature) at baseline, every 4 hours during the
study, and at the end of both periods. Subjects were asked if they experienced any AEs
during the study. Laboratory analyses (ECG, serum biochemistry, and urinalysis) were
also performed before and after the study. Only descriptive statistics were reported for
the assessment.
PHARMACOKINETIC ANALYSIS
A total of 24 subjects were used in this study, and the sample size was determined
to achieve 80% power with a 90% CI. 16
The pharmacokinetic parameters of amoxicillin were calculated using a noncom-
partmental method with Kinetica version 4.4.1 software (Thermo Electron Corpora-
tion, Basingsroke, United Kingdom). The C
max
of amoxicillin was determined by
visual inspection of the serum concentration-time profile and the t 1l2 was calculated
using the following equation17:
where kef was the terminal elimination rate constant calculated using linear least
squares regression of the last 3 to 4 time points in the log concentration-time profile.
The AUC from time zero to the last sampling time (AUCO_tlast) was calculated using
the linear trapezoidal rule.l? AUCo_oo was calculated as follows:
The mean residence time (MRT) was calculated as follows:
MRT = AUMCo_=
AUC '0-00
where AUMC was area under the moment curve.
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STATISTICAL ANALYSIS
The analytical method used to measure the 2 formulations of amoxicillin was vali-
dated for accuracy, precision, linearity, and sensitivity. Pharmacokinetic parameters
were calculated for both the test and reference products using SPSS version 12 .0
(SPSS Inc. , Chicago, Illinois). P < 0.05 was considered statistically significant.
The within-group and between-group differences were examined using analysis of
variance, with P < 0.05 being considered statistically significant. The effects of for-
mulation, period, sequence, and subject were analyzed according to the statistical
model of Jones and Kenward.!" Log-transformed values of the pharmacokinetic pa-
rameters were used in the model and the formulation , period, sequence, and subject
effects were evaluated.
Large sample-based 90% CIs for the pharmacokinetic parameters (obtained for both
formulations) from log-transformed data were evaluated to assess bioequivalence. The
formulations were considered bioequivalent if the natural log (In)-transformed ratios of
pharmacokinetic parameters were within the predetermined equivalence range of 80%
to 125%, according to the US Food and Drug Administration (FDA) requiremenr.J?
RESULTS
SUB.JECTS
Twenty-four healthy adult male Bangladeshi volunteers (mean [SD) age, 26 .92
[3.37) years; age range, 23-34 years; mean [SD} body mass index, 23.09 [1.58} kg/rrr')
participated in the study. No volunteers were withdrawn from the study.
METHOD VALIDATION
The HPLC method with UV detection used for drug quantification provided
the appropriate sensitivity, specificity, and high sample throughput required for
pharmacokinetic srudies.I ? The retention times for amoxicillin and cefaclor (in-
ternal standard) were found to be 3.88 and 15 minutes, respectively. The relation-
ship between concentration and peak area ratio was found to be linear within the
range of 0.1 to 10 ~g/mL for amoxicillin (r2 > 0 .997). The limit of quantification
was 0.1 ug/rnl.. The intraday accuracy of the method used to measure serum
amoxicillin concentration ranged from 101.5 % to 108.3%, and the intraday pre-
cision ranged from 5.7 % to 14.0%. The interday accuracy ranged from 101.5 %
to 108.4%, and the inrerday precision was 5.9% to 14.4% for serum standards.
The absolute recovery of amoxicillin from serum was 97.2% and that of cefaclor
was 96.5%. No significant degradation of amoxicillin in serum was observed dur-
ing this period.
SERUM PHARMACOKINETIC ANALYSIS
The plot of mean serum concentration (N = 24) versus time over a period of
12 hours for all volunteers is shown in the figure.
Paired t tests were done for all the parameters at the 5% level of significance. There were
no significant between-group differences for any of the pharmacokinetic parameters
(Table I). Amoxicillin was absorbed rapidly, with a mean (SD) T max of 1.29 (0.58) and
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Figure. Mean (SO) amoxlcillin concentration-versus-time curve over 12 hours in healthy
adult male Bangladeshis (N = 24). *5K-mox® (Eskayef Bangladesh Ltd., Dhaka,
Bangladesh); tAmoxil-Bencard® (SmithKline Beecham pic, Middlesex, United
Kingdom).
Table I. Mean (SO) serum pharmacokinetic parameters for test* and referencet formula-
tions of amoxiclllin SOO-mg capsules In healthy adult male Bangladeshis.
Pharmacokinetic Test Reference
Parameter (n = 24) (n = 24) P
Cmax ' ug/rnl, 9.85 (2.73) 10.63 (2.12) 0.26
Tmax ' h 1.29 (0.58) 1.33 (0.49) 0.84
AUCO_12 ' ug/mt, . h-1 27.09 (7.62) 28.56 (6.30) 0.16
AUCo_~' ug/rnt, . h-1 29.47 (10.21) 29.32 (6.27) 0.93
t 1/ 2 , h 3.05 (1.78) 3.24 (1.19) 0.78
kei' h-1 0.29 (0.14) 0.25 (0.13) 0.52
AUMCo_12 ' ug/rnt, . h-1 90.15 (42.99) 93.41 (29.84) 0.65
AUMCo_~' ~g/mL . h-1 134.84 (107.50) 121.31 (42.04) 0.62
MRT, h 4.17 (2.05) 4.00 (1.03) 0.78
kel = terminal elimination rate constant; AUMC = area under the moment curve; MRT = mean residence
time.
*SK-mox® (Eskayef Bangladesh Ltd., Dhaka, Bangladesh).
t Amoxil-Bencarde (SmithKline Beecham pic, Middlesex, United Kingdom).
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1.33 (0.49) hours for the test and reference formulations, respectively. C
m ax
(9.85
[2.73} vs 10.63 [2.12} pg/rnl.) and AUCO-12 (27.09 [7.62} vs 28.56 [6.30} pg/rnl, . h")
for amoxicillin were also similar after administration of the test and reference capsules,
respectively.
STATISTICAL ANALYSIS FOR BIOEQUIVALENCE
Analysis of variance for the crossover design18 was used to assess the formulation,
period, sequence, and subject effects on the serum pharmacokinetic parameters. The
parameters were not significantly different in terms of variation in formulation, pe-
riod, or sequence. Significant variation was observed among subjects in AUCO_ 12 (P <
0.001), AUCo_oo (P = 0.002), AUMCo_12 (P < 0.001), and AUMCo_oo (P = 0.017)
(Table II).
C
max
and AUCO_ 12 for the serum data were analyzed statistically to determine
bioequivalence. Large sample-based 90% CIs on the mean of the difference between
the 2 formulations were computed. The estimates of 90% CIs for the ratio of these
parameters were found to be within 80% to 125% for In-transformed data, as required
by the FDA for drug bioequivalence (Table III).
TOLERABILITY
All 24 volunteers completed the study without any AEs occurring during the
12-hour follow-up, as assessed by monitoring vital signs and laboratory analysis.
No vomiting, diarrhea, or other AEs were reported during the study period.
DISCUSSION
Evaluation of the bioequivalence of a test drug and a reference drug is tequired to
exclude any clinically important differences in the rate or extent to which the active
entity of the drugs becomes available at the site of action. The FDA considers 2 drugs
bioequivalent if they are pharmaceutically equivalent and their bioavailabilities are so
similar that they are unlikely to produce clinically relevant differences in regard to
tolerability and efficacy.l?
The pharmacokinetic parameters obtained with the test and reference formula-
tions were not significantly different, which reflects the comparable pharmacoki-
netic characteristics of the 2 formulations. The 90% CIs for Cm ax ' AUCO_ 12' and
AUCo_= were within the acceptable range (80%-125%) based on the FDA criteria
for bioequivalence. Moreover, both formulations were well tolerated.
This study was limited by the small sample size of healthy volunteers and by the
use of only a single dose of amoxicillin. Larger studies in both healthy volunteers and
patients are needed to obtain more definitive results and to compare the pharmacoki-
netic characteristics of different races.
CONCLUSION
The present study suggests that the test formulation 500-mg amoxicillin capsule was
bioequivalent to the reference formulation, according to the FDA regulatory defini-
tion, in this population of healthy adult male Bangladeshi volunteers.
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Table II. P values for variations between test* and reference t amoxicillin formulations in healthy adult male Bangladeshis based
on formulation, period, sequence, and subject using analysis of variance.
Source of Variation Cmax Tmax AUCO_12 AUCo_oo kel t 1/ 2 AUMCo_12 AUMCo_w MRT
Formulation 0 .302 0.254 0.659 0.725 0.795 0.794 0.271 0.537 0.390
Period 0.242 0.731 0.159 0.616 0.602 0.603 0.218 0.595 0.884
Sequence 0.94 0.567 0.792 0.696 0.815 0.814 0.915 0.983 0 .805
Subject 0.036 0.291 <0.001 0.002 0.798 0.798 <0.001 0.017 0.124
kel =terminal elimination rate constant; AUMC=area under the moment curve; MRT =mean residence time .
* SK·mox4'; (Eskayef Bangladesh Ltd., Dhaka, Bangladesh).
t Arnoxlf-Bencard" (SmithKline Beecham pic, Middlesex, United Kingdom).
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Table III. Large, sample-based 90% Cis for the pharmacokinetic
parameters of healthy adult male Bangladeshis admin-
istered amoxicillin 500 mg.
Parameter Point Estimate
91.33
93.12
94.11
90%CI
82.58-101.02
87.54-99.05
86.50-102.38
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